Prelude Capital Management, LLC Taysha Gene Therapies, Inc. Transaction History

Prelude Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.04 - $4.17 $266,623 - $545,010	130,698 Added 233.84%	186,591 $417,000
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $191,595 - $435,444	-133,983 Reduced 70.56%	55,893 $160,000
Q4 2023 Feb 14, 2024	SELL	$1.33 - $2.88 $66,998 - $145,080	-50,375 Reduced 20.97%	189,876 $336,000
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $151,358 - $879,318	240,251 New	240,251 $759,000

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.